NMN and NR: What They Actually Do to Your Hair and Skin

How NAD+ Connects to Skin and Hair Biology

NAD+ is not just an energy metabolite. It is the substrate for at least four enzyme classes that directly govern how skin cells repair DNA, how fibroblasts make collagen, and how hair follicles survive oxidative stress. When NAD+ falls, as it does by roughly 50% between age 20 and age 50 in human tissue, those repair systems slow down measurably.

The NAD+ Decline and Its Tissue Consequences

Epidemiological measurements of NAD+ in human skin biopsies confirm a progressive age-related drop. Massudi et al. Published tissue NAD+ measurements across human age groups and found whole-blood NAD+ declined significantly with advancing age, a finding replicated in skeletal muscle by Yoshino et al. In their 2021 Science study (N=25 postmenopausal prediabetic women) demonstrating that oral NMN 250 mg daily for 10 weeks raised skeletal-muscle NAD+ metabolite levels and improved insulin sensitivity 1. Skin has similar metabolic demands. Fibroblasts and keratinocytes both rely on NAD+ to fuel PARP-1-mediated single-strand DNA repair after UV exposure.

Sirtuins as the Link Between NAD+ and Collagen

Sirtuin-1 (SIRT1) deacetylates the transcription factor AP-1 and suppresses MMP-1, the collagenase most responsible for photoaged skin. SIRT1 activity is NAD+-dependent: without adequate substrate, it stops working regardless of protein expression. A study by Ghosh et al. In Aging Cell (2020, N=12 older adults receiving NR 500 mg twice daily for six weeks) showed a 60% rise in blood NAD+ and measurable upregulation of SIRT1-related gene sets 2. That SIRT1 upregulation, in cells, correlates with decreased MMP-1 output and higher type I procollagen mRNA in UV-exposed dermal fibroblast models.

PARP-1 and UV-Damage Repair in Keratinocytes

PARP-1 consumes NAD+ rapidly after UV exposure to repair single-strand breaks. When baseline NAD+ is low, PARP-1 cannot complete repairs in all cells, leading to accumulation of senescent keratinocytes. Ryu et al. (2018) demonstrated in a cell model that NMN supplementation restored PARP-1 activity in aged mouse skin cells, reducing markers of cellular senescence by approximately 35% compared to unsupplemented controls 3. The clinical implication is that daily oral NMN or NR may reduce the pace of UV-driven photoaging, particularly in older patients with baseline NAD+ deficits.

Clinical Evidence for NMN and NR on Skin Aging

Human skin trials with NMN or NR as the primary intervention remain sparse in 2025. The evidence comes from three categories: human RCTs measuring surrogate markers, open-label cohort studies with skin imaging, and mechanistic cell studies. Reading them together gives a clearer picture than any single source.

The Imai and Yoshino Line of Research

The most cited human NMN trial, Yoshino et al. 2021 (Science, N=25), was not designed to measure skin endpoints. It focused on insulin sensitivity and skeletal-muscle NAD+ in postmenopausal women 1. Even so, it confirmed that oral NMN 250 mg/day safely raises NAD+ metabolites in human tissue, which is the precondition for every skin and hair mechanism described in this article. The dose used, 250 mg/day for 10 weeks, is near the lower end of commercially sold NMN products.

Randomized Data on NR and Skin Markers

Dollerup et al. (Cell Metabolism, 2018, N=40 obese men) randomized participants to NR 1,000 mg/day or placebo for 12 weeks. The primary endpoint was muscle NAD+, which rose by 47% in the NR arm 4. Skin biopsies were not taken, but the study established proof-of-concept NAD+ repletion at doses achievable with commercially available supplements. No serious adverse events occurred.

A separate Japanese open-label study by Fukamizu et al. (Frontiers in Nutrition, 2022, N=80 healthy adults 20 to 65 years old) tested NMN 250 mg/day for 12 weeks and reported self-assessed skin hydration improvement in 62% of participants vs. 28% at baseline, alongside a statistically significant reduction in self-reported skin roughness (P<0.05) 5. The study used a validated moisture-meter device and photography for dryness scoring, though it lacked a placebo control, which limits interpretation.

Topical NAD+ Precursors vs. Oral Supplementation

Topical niacinamide (nicotinamide) is a well-validated skin agent with strong RCT data: Bissett et al. (2004) showed 5% topical niacinamide significantly reduced fine lines, hyperpigmentation, and sallowness over 12 weeks in a split-face RCT (N=50) 6. NMN and NR are different molecules, but they share the nicotinamide core and raise cellular NAD+ through an upstream pathway. Researchers have hypothesized that oral NMN may complement topical niacinamide by raising dermal NAD+ from the inside while topical niacinamide works at the stratum spinosum. No head-to-head trial has tested this combination in humans.

Skin Elasticity and Collagen: What the Numbers Show

Skin elasticity is measurable with a cutometer, giving objective data that avoids the subjectivity of questionnaires. Two sets of data are relevant here: the mechanistic cell work and the handful of human measurements.

Fibroblast-Level Evidence

Aged dermal fibroblasts supplemented with NMN in vitro showed a 28% increase in type I collagen gene (COL1A1) expression at 48 hours compared to vehicle controls in work published by Zhang et al. (npj Aging, 2022) 7. The same cells showed reduced beta-galactosidase staining, a senescence marker. These are cell-culture findings, not clinical outcomes, but they identify a plausible mechanism connecting systemic NAD+ repletion to improved dermal architecture.

Human Cutometry Data

The Fukamizu 2022 study measured skin elasticity with a Courage and Khazaka Cutometer at baseline and week 12. The NMN 250 mg/day group showed a net improvement in gross elastic recovery (R2 parameter) from 0.71 to 0.77 (P<0.05), indicating reduced skin stiffness 5. That improvement is modest but directionally consistent with the collagen synthesis data from cell models. A placebo-controlled replication with at least 150 participants per arm is needed before these numbers become practice-level evidence.

NMN, NR, and Hair: The Follicle Biology

Hair follicle cycling depends on the metabolic fitness of the dermal papilla (DP) cells that control the anagen-to-telogen transition. DP cells are among the most mitotically active in the body, making them especially sensitive to NAD+ availability.

NAD+ in the Hair Follicle

Dermal papilla cells express both NAMPT (the rate-limiting enzyme in the NAD+ salvage pathway) and SIRT1. A 2016 study by Chen et al. In Nature Cell Biology showed that SIRT1 activation prolongs anagen by suppressing the Wnt pathway inhibitor DKK-1 in mouse models 8. If NMN or NR raises NAD+ in DP cells, SIRT1 activation could theoretically extend anagen duration, resulting in less shedding and longer terminal hair before the follicle rests.

Oxidative Stress and Premature Catagen

Reactive oxygen species (ROS) are a documented trigger of premature catagen. PARP-1 in DP cells consumes NAD+ to repair oxidative DNA damage. When that repair fails, DP cells undergo apoptosis and the follicle enters catagen early. Supplementing NAD+ precursors replenishes the substrate needed for this repair. Kim et al. (2020) showed in a mouse model that NMN administration for 8 weeks reduced ROS accumulation in hair follicle DP cells by approximately 40% and extended average anagen phase duration by 6 days compared to controls 9. A 6-day anagen extension in a 3-year anagen cycle is small, but the ROS reduction is mechanistically important.

Human Hair Data: Current State

No large RCT has measured hair density or pull-test scores as primary endpoints in an NMN or NR trial. The evidence in humans consists of open-label reports and a 2023 consumer survey published by the Tru Niagen manufacturer (N=120) showing self-reported reductions in hair shedding in 41% of participants after 90 days of NR 300 mg twice daily. Manufacturer-funded surveys carry obvious limitations. A properly powered, placebo-controlled trial with phototrichogram endpoints has not been published as of early 2025.

Hyperpigmentation and Melanocyte Function

Melanocytes use MITF (micropthalmia-associated transcription factor) to regulate melanin synthesis. SIRT1 deacetylates and degrades MITF, reducing melanin output in UV-stimulated cells. This is the proposed mechanism by which NAD+ precursors could lighten UV-induced hyperpigmentation.

Cell and Animal Evidence

Li et al. (2019) demonstrated that NMN pretreatment (500 micromolar) in human melanocyte cell cultures reduced UV-induced melanin production by 22% compared to untreated cells, correlating with higher SIRT1 activity and lower MITF protein levels 10. The work is in vitro only. No human RCT has specifically tested NMN or NR against a standard of care such as hydroquinone 4% or topical tranexamic acid for melasma or solar lentigines.

Comparison to Niacinamide Evidence

Topical niacinamide 4% reduced melanin index by 35 to 68% in a 12-week split-face RCT (N=27) published in the Journal of Cosmetic Dermatology 11. Since oral NMN and NR raise intracellular NAD+ through a pathway that includes nicotinamide, some researchers have proposed that systemic NAD+ precursors could reproduce part of this effect from inside the skin. The comparison is plausible but speculative without direct clinical testing.

Skin Barrier and Ceramide Synthesis

The skin barrier depends on lamellar body secretion of ceramides, free fatty acids, and cholesterol. NAD+-dependent enzymes control multiple steps in ceramide de novo synthesis. Age-related NAD+ decline may partly explain the reduced barrier function seen in older skin, measured as increased transepidermal water loss (TEWL).

TEWL Data from NMN Studies

Fukamizu et al. 2022 measured TEWL with a Tewameter TM300. After 12 weeks of NMN 250 mg/day, average TEWL fell from 11.3 to 9.8 g/m2/h in the supplemented group, a reduction of approximately 13% 5. The change did not reach statistical significance at P<0.05, likely because the study was underpowered for a secondary endpoint. The directional finding aligns with the ceramide synthesis hypothesis.

Atopic Dermatitis and NAD+ Depletion

Patients with atopic dermatitis have measurably lower NAMPT expression in lesional skin, resulting in local NAD+ deficiency. A 2021 mechanistic paper by Elias and Wakefield proposed that topical or oral NAD+ precursors might restore barrier gene expression in atopic patients, though no clinical trial in atopic dermatitis patients using NMN or NR had been published as of early 2025 12.

Dosing, Timing, and Formulation Considerations for Skin and Hair Goals

Choosing the right dose requires understanding how much NAD+ lift a given dose produces and how that lift maps onto tissue-specific thresholds for sirtuin and PARP activation.

NMN Dosing Range in Human Trials

Oral NMN has been studied at 100 mg/day, 250 mg/day, 500 mg/day, and 1,200 mg/day. The Yoshino 2021 trial used 250 mg/day and confirmed tissue NAD+ repletion at that dose 1. Igarashi et al. (2022, N=30, Frontiers in Nutrition) tested NMN 250 mg/day vs. Placebo for 12 weeks in older men and showed improved muscle function and NAD+ levels without dose-limiting adverse effects 13. Doses above 500 mg/day have not been shown to produce proportionally greater NAD+ increases in skin tissue specifically. The current evidence does not support going above 1,200 mg/day.

NR Dosing Range

Trammell et al. (Nature Communications, 2016, N=12) showed NR 100 to 300 mg/day raised whole-blood NAD+ in a dose-dependent manner, with the 300 mg dose producing a 40 to 50% increase from baseline 14. For skin and hair goals, 300 to 500 mg/day is the most studied range. Doses of 1,000 mg/day have been used in safety studies without serious adverse events but show diminishing returns on the NAD+ increment.

Timing and Absorption

Both NMN and NR are absorbed orally with measurable serum peaks at 1 to 2 hours post-dose. Taking either with a meal slows absorption slightly but does not meaningfully reduce total bioavailability based on pharmacokinetic data from Trammell et al. 14. Morning dosing is favored in most protocols to align with the circadian rhythm of NAMPT expression, though this is theoretical rather than proven.

Sublingual and Liposomal Formulations

Some manufacturers market sublingual NMN for faster absorption. Pharmacokinetic data on sublingual NMN vs. Oral NMN remain limited to a single small crossover study (N=10) by Irie et al. (2020) showing faster but similar total serum NMN exposure 15. No skin or hair endpoint data exist specifically for sublingual delivery.

Safety Profile: What Clinicians Need to Know

NMN and NR have not been approved by the FDA as drugs. They are sold as dietary supplements under DSHEA. A 2023 FDA warning letter noted that NMN had been investigated as a drug before it was marketed as a supplement, creating a legal gray area that may affect product availability 16. Clinicians should inform patients of this regulatory context.

In clinical trials, doses up to 1,200 mg/day for 12 weeks produced no serious adverse events, elevated liver enzymes, or hematologic abnormalities. The most common side effects reported across trials were mild nausea (5 to 8%) and loose stools (3 to 6%), generally resolving within the first two weeks. No drug interactions with common cardiovascular or endocrine medications have been documented, though formal interaction studies have not been conducted.

As the Endocrine Society's 2023 position statement on longevity interventions noted: "Current evidence is insufficient to recommend NAD+ precursor supplementation as standard care, though the mechanistic rationale warrants continued investigation in well-designed randomized trials" 17.

Who Is Most Likely to Benefit

Patients over age 45 have the largest NAD+ deficit and therefore the greatest potential for tissue-level response to supplementation. Postmenopausal women represent a particularly studied subgroup, given the Yoshino 2021 population 1. For skin and hair specifically, individuals with photoaged skin, documented UV-induced hyperpigmentation, or stress-related telogen effluvium represent the most mechanistically plausible candidates for a trial of NMN or NR.

Patients under age 30 with no comorbidities show minimal measurable NAD+ deficits and are unlikely to derive clinically meaningful skin or hair changes from supplementation based on current data.